Vidula, Neelima Ellisen, Leif W. Bardia, Aditya
Published in
Oncotarget
Plasma based genotyping via cell-free DNA may identify actionable mutations for potential therapeutic intervention in patients with advanced malignancies including breast cancer. In this article, we discuss recent studies using cell-free DNA testing to identify and classify somatic BRCA1/2 mutations in metastatic breast cancer, and potential future...
Osapoetra, Laurentius O. Sannachi, Lakshmanan Quiaoit, Karina Dasgupta, Archya DiCenzo, Daniel Fatima, Kashuf Wright, Frances Dinniwell, Robert Trudeau, Maureen Gandhi, Sonal
...
Published in
Oncotarget
Purpose: We develop a multi-centric response predictive model using QUS spectral parametric imaging and novel texture-derivate methods for determining tumour responses to neoadjuvant chemotherapy (NAC) prior to therapy initiation. Materials and Methods: QUS Spectroscopy provided parametric images of mid-band-fit (MBF), spectral-slope (SS), spectral...
Hilbers, Marie-Luise Brändli, Regula Mühleisen, Beda Freiberger, Sandra N. Mangana, Joanna Dummer, Reinhard
Published in
Oncotarget
Importance: Spitzoid lesions are a group of melanocytic tumors characterized by spindle-like or epithelioid cells with variable malignant potential. While some spitzoid lesions are classified as evidently benign or malignant by clinic and histology, others present with unclear clinical and histological characteristics and are categorized as lesions...
Kitajima, Kazuhiro Miyoshi, Yasuo Sekine, Tetsuro Takei, Hiroyuki Ito, Kimiteru Suto, Akihiko Kaida, Hayato Ishii, Kazunari Daisaki, Hiromitsu Yamakado, Koichiro
...
Published in
Oncotarget
Objectives: This study investigated harmonized pretreatment volume-based quantitative FDG-PET/CT parameters in breast cancer patients for prognostic value. Results: During a median overall follow-up period of 5.3 years, 91 patients had recurrence and 40 died. Multivariate analysis of ER-positive/HER2-negative patients showed high maximum standardiz...
Abdelaal, Gina Veuger, Stephany
Published in
Oncotarget
Cancer cells accumulate iron to supplement their aberrant growth and metabolism. Depleting cells of iron by iron chelators has been shown to be selectively cytotoxic to cancer cells in vitro and in vivo . Iron chelators are effective at combating a range of cancers including those which are difficult to treat such as androgen insensitive prostate c...
Pérez-Lorenzo, Rolando Erjavec, Stephanie O. Christiano, Angela M. Clynes, Raphael
Published in
Oncotarget
The use of specific anti-tumor antibodies has transformed the solid cancer therapeutics landscape with the relative successes of therapies such as anti-HER2 in breast cancer, and anti-EGFR in HNSCC and colorectal cancer. However, these therapies result in toxicity and the emergence of resistant tumors. Here, we showed that removing immune suppressi...
Ko, Juyeon Meyer, April N. Haas, Martin Donoghue, Daniel J.
Published in
Oncotarget
Metastatic castrate-resistant prostate cancer (CRPC) remains uncurable and novel therapies are needed to better treat patients. Aberrant Fibroblast Growth Factor Receptor (FGFR) signaling has been implicated in advanced prostate cancer (PCa), and FGFR1 is suggested to be a promising therapeutic target along with current androgen deprivation therapy...
Zhou, Pengjun Zhang, Rong Wang, Ying Xu, Dandan Zhang, Li Qin, Jinhong Su, Guifeng Feng, Yue Chen, Hongce You, Siyuan
...
Published in
Oncotarget
Crosby, Erika J. Lyerly, H. Kim Hartman, Zachary C.
Published in
Oncotarget
Gupta, Nitasha Lampert, Erika Lee, Jung-Min
Published in
Oncotarget
